Effect of soy protein supplementation in patients with chronic hepatitis C: A randomized clinical trial

Table 3 Comparison of the distribution of hepatic steatosis before and after intervention between groups of patients with hepatitis C virus

Hepatic Steatosis	n	Yes	No	P value
Before				0.26041
IG-soy	64	19 (29.7)	45 (70.3)
CG-casein	60	24 (40.0)	36 (60.0)
After				0.18501
IG-soy	64	10 (15.6)	54 (84.4)
CG-casein	60	16 (26.7)	44 (73.3)
IG-soy: before vs after				0.0076 2
With hepatic steatosis	19	10 (52.6)	9 (47.4)
Without hepatic steatosis	45	0 (0.0)	45 (100.0)
GC-casein: before vs after				0.01332
With hepatic steatosis	24	16 (66.7)	8 (33.3)
Without hepatic steatosis	36	0 (0.0)	36 (100.0)

¹Fisher's exact test: Comparison between groups before and after intervention;

²Paired analysis: McNemar’s test: Comparison in each group. CG-casein: Control group-casein; IG-soy: Intervention group-soy.